M3315
MJ33 lithium salt
≥90% (NMR), phospholipase A2 (PLA2) inhibitor , powder
Synonym(s):
1-Hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol lithium
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C22H43F3O6PLi
CAS Number:
Molecular Weight:
498.48
UNSPSC Code:
41106300
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥90% (NMR)
Form:
powder
Product Name
MJ33 lithium salt, powder, ≥90% (NMR)
Quality Segment
assay
≥90% (NMR)
form
powder
color
white to beige
solubility
H2O: ≥5 mg/mL (warmed at 60 °C)
storage temp.
2-8°C
SMILES string
CCCCCCCCCCCCCCCCOCC(COCC(F)(F)F)OP(OC)([O-])=O.[Li+]
InChI
1S/C22H44F3O6P.Li/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-29-18-21(31-32(26,27)28-2)19-30-20-22(23,24)25;/h21H,3-20H2,1-2H3,(H,26,27);/q;+1/p-1
InChI key
GDLMLQJISATCEL-UHFFFAOYSA-M
Application
MJ33 lithium salt has been used as a peroxiredoxin VI (Prdx6) inhibitor:
- to study its specific Prdx6 peroxidase activity in vitro and in breast cancer cell line (MCF-7) cell lysates
- to study its effects on a mouse model of acute lung injury associated with exposure to hyperoxia
- to study its potential use as a therapeutic agent
Biochem/physiol Actions
MJ33 acts as a non-toxic and potent inhibitor of agonist-induced activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase type 2 (NOX2). It also prevents lung injuries associated with lung inflammation in mice. MJ33 is a fluorinated lipid analog, which blocks the enzyme by mimicking the transition state of the substrate.
Novel, active site directed, specific, competitive and reversible inhibitor of phospholipase A2 (PLA2).
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.